HKU Scholars Hub: Browsing DSpace

Browsing by Author Yen, CJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date	Views
	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma Journal:Clinical Cancer Research	Yau, TCC Lencioni, R Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Camp, A Cox, DS Gagnon, R Liu, Y Raffensperger, KE Kulkarni, D Kallender, H Ottesen, LH Poon, RTP Bottaro, DP	2017	90
	A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology	Yau, TCC Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Lencioni, R Camp, AC Cox, DS Kallender, H Ottesen, LH Poon, RTP	2012	110
	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Journal:Therapeutic Advances in Medical Oncology	Qin, S Chan, SL Sukeepaisarnjaroen, W Han, G Choo, SP Sriuranpong, V Pan, H Yau, T Guo, Y Chen, M Ren, Z Xu, J Yen, CJ Lin, ZZ Manenti, L Gu, Y Sun, Y Tiedt, R Hao, L Song, W Tanwandee, T	2019	3
	A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Hepatology	Yau, T Yen, CJ Chen, PJ Chau, Y Lencioni, R Kallender, H Ottesen, LH Poon, RTP	2011	135
	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology	Yau, TCC Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Lencioni, R Camp, AC Cox, DS Kallender, H Ottesen, LH Poon, RTP	2012	105
	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018	1
	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study Journal:European Journal of Cancer	Chau, I Peck-Radosavljevic, M Borg, C Malfertheiner, P Seitz, JF Park, JO Ryoo, BY Yen, CJ Kudo, M Poon, RTP Pastorelli, D Blanc, JF Chung, HC Baron, AD Okusaka, T Bowman, L Cui, ZL Girvan, AC Abada, PB Yang, L Zhu, AX	2017	9
	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Journal:The Lancet Oncology	Zhu, AX Park, JO Ryoo, BY Yen, CJ Poon, RTP	2015	48
	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma Journal:Journal of Hepatology	Abou-Alfa, GK Puig, O Daniele, B Kudo, M Merle, P Park, JW Ross, P Peron, JM Ebert, O Chan, S Poon, RTP Colombo, M Okusaka, T Ryoo, BY Minguez, B Tanaka, T Ohtomo, T Ukrainskyj, S Boisserie, F Rutman, O Chen, YC Xu, C Shochat, E Jukofsky, L Reis, B Chen, G Di Laurenzio, L Lee, R Yen, CJ	2016	29

Showing results 1 to 9 of 9